Cargando…

Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis

The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levin, Myron J., Divino, Victoria, Shah, Drishti, DeKoven, Mitch, Mould-Quevedo, Joaquin, Pelton, Stephen I., Postma, Maarten J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540032/ https://www.ncbi.nlm.nih.gov/pubmed/34696254 http://dx.doi.org/10.3390/vaccines9101146

Ejemplares similares

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
por: Pelton, Stephen I., et al.
Publicado: (2020)

14. A Comprehensive Real-World Analysis to Compare Adjuvanted Trivalent Influenza Vaccine and Trivalent High Dose Influenza Vaccine by Age and Period of High Influenza Activity for the 2018–19 Season among U.S. Elderly
por: Postma, Maarten, et al.
Publicado: (2020)

29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season
por: Postma, Maarten, et al.
Publicado: (2020)

6. MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018–19 Influenza Season
por: Pelton, Stephen I, et al.
Publicado: (2020)

A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States
por: Divino, Victoria, et al.
Publicado: (2021)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

The Impact of Adjuvanted Influenza Vaccine on Disease Severity in the US: A Stochastic Model
por: Pelton, Stephen I., et al.
Publicado: (2023)

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
por: Nguyen, Van Hung, et al.
Publicado: (2023)

1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
por: Nguyen, Van, et al.
Publicado: (2018)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
por: Boikos, Constantina, et al.
Publicado: (2022)

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine
por: Cox, Freek, et al.
Publicado: (2015)

Estimating the Impact of Influenza Vaccination on Acute and ICU Hospital Bed Usage in an Influenza Season under Endemic COVID-19 in the US
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Return-to-Function Following Treatment of Dupuytren Contracture With Collagenase Clostridium Histolyticum Versus Fasciectomy
por: Divino, Victoria M., et al.
Publicado: (2020)

Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review
por: Mould-Quevedo, Joaquin F., et al.
Publicado: (2023)

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
por: Postma, Maarten, et al.
Publicado: (2023)

1166. The Cost-Effectiveness Evidence of Enhanced Influenza Vaccines in Adults ≥65 Years of Age: A Literature Review and Decision-Making Implications
por: Giglio, David FismanNorberto, et al.
Publicado: (2023)

The economic burden of CIDP in the United States: A case-control study
por: Divino, Victoria, et al.
Publicado: (2018)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

1167. The Value of Influenza Vaccination in the Older Adult Population. A Stochastic Model Estimation of the benefit of vaccination to prevent the Severe Outcomes in the U.S.
por: Pelton, Stephen I, et al.
Publicado: (2023)

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults
por: Ambrose, Christopher S., et al.
Publicado: (2010)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis
por: Coleman, Brenda L., et al.
Publicado: (2021)

Acquired immune responses to the seasonal trivalent influenza vaccination in COPD
por: Staples, K. J., et al.
Publicado: (2019)

Estimating the impact of influenza vaccination of low-risk 50–64-year-olds on acute and ICU hospital bed usage in an influenza season under endemic COVID-19 in the UK
por: Nguyen, Van Hung, et al.
Publicado: (2023)

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data
por: Divino, Victoria, et al.
Publicado: (2019)

Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study
por: de Lusignan, Simon, et al.
Publicado: (2022)

Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military
por: Gao, Dongqi, et al.
Publicado: (2016)

Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine
por: Demeulemeester, Marc, et al.
Publicado: (2016)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom
por: Maschio, Michael, et al.
Publicado: (2022)

Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis
por: Divino, Victoria, et al.
Publicado: (2016)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
por: de Boer, Pieter T., et al.
Publicado: (2018)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

PIN75 Characteristics of Patients Diagnosed with COVID-19 in the US: A Descriptive Claims-Based Study from a National Perspective
por: Divino, V., et al.
Publicado: (2020)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9qpemn016a33len9d2i3kcigso